What is the most serious side effect of dasatinib/tasatinib?

Dasatinib (Dasatinib) is a second-generation BCR-ABL tyrosine kinase inhibitor, mainly used for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Although its efficacy is remarkable, it is also accompanied by certain risks during clinical use. Some of the side effects may be life-threatening and are therefore considered the most serious.

Among the reported adverse reactions, pleural effusion is one of the most common and potentially serious complications of dasatinib use. Pleural effusion may cause dyspnea, cough and chest tightness, requiring timely clinical intervention, including drug reduction or discontinuation, and even thoracic puncture to drain the fluid in severe cases. In addition, dasatinib can cause cardiovascular system-related problems, such as atrial fibrillation, atrial flutter, and QT interval prolongation. Especially for patients with basic cardiovascular diseases, electrocardiogram and cardiac function must be strictly monitored during medication to prevent serious arrhythmias and heart failure.

Adverse reactions to the blood system cannot be ignored. Dasatinib may cause severe myelosuppression, including neutropenia, thrombocytopenia, and anemia, and increase the risk of infection and bleeding. In some cases, myelosuppression can lead to life-threatening complications that require management with drug discontinuation, dose adjustment, and supportive care. Hepatic and renal function impairment is also a potential serious side effect of dasatinib, especially hepatotoxicity and hepatitis B virus reactivation, which may aggravate the patient's overall condition.

In addition, rare but serious complications such as interstitial lung disease, thrombotic microangiopathy, Stevens-Johnson syndrome, and nephrotic syndrome also deserve attention. These adverse reactions often require multidisciplinary collaboration to evaluate and intervene to ensure that patients minimize risks during treatment.

Reference materials:https://go.drugbank.com/drugs/DB01254